{
  "retracted": false,
  "timestamp": 1576627200000,
  "updates": [
    {
      "timestamp": 1591711534945,
      "identifier": {
        "doi": "10.1186/s12913-019-4829-z"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1186/s12913-019-4680-2"
  },
  "journal": "BMC Health Services Research",
  "publisher": "Springer Science and Business Media LLC",
  "title": "Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis"
}
